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Abstract
Poly(N-isopropyl acrylamide)  block  poly(ethylene glycol)  block  poly(N-isopropyl acrylamide) is 
known to exhibit a thermally-induced solution-to-gel transition in water, which may be exploited for 
biomedical applications. This thermoreversible gelator has great potential for application in topical 
administration to the surfaces of the body such as the skin, eye, and vagina, but this has not yet been 
evaluated. This study evaluates PNIPAM98-PEG122-PNIPAM98 as a thermoreversible gelator for vaginal 
administration, for the first time evaluating the effect of polymer concentration on gelation, studying 
rheological parameters relevant to topicals, measuring dissolution rates, stability and the phenomemon 
of mucoadhesion. Two drugs relevant to vaginal administration, progesterone and tenofovir disoproxil 
fumarate are investigated for use in the thermoreversible gelators, studying both hydrophobic and 
hydrophilic drug solubilisation and release. Throughout the study, comparison is made with poloxamer 
407, the most commonly studied thermoreversible gelator. PNIPAM98-PEG122-PNIPAM98 exhibits several 
advantages for topical administration, having low viscosity at room temperature to allow easy application, 
then exhibiting a gelation just below body temperature to form a viscous gel which is resistant to 
dissolution and relatively mucoadhesive. Drug release is highly dependent on temperature, with elevation 
to body temperature resulting in a dramatic retardation of progesterone release, which may be used in 
future medicines to provide sustained delivery of hydrophobic xenobiotics. 
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Introduction
Smart materials respond to external stimuli by alteration of one or more of their physical properties. 
One class of smart material are thermoreversible gelators. These materials undergo a solution-to-gel 
transition when warmed above a critical temperature (Tgel), exhibiting the reverse gel-to-solution phase 
change upon cooling.1 Thermoreversible gelators with a Tgel occurring between room temperature (ca 
25°C) and body temperature (37 °C internally) may pass through an applicator or syringe, then form a 
viscous gel on contact with the body.2 This in situ gelation may be used for injectables, where the gel may 
act as a drug depot or scaffold for therapeutic cells 3, and for topical administration to either skin or 
mucosal membranes.4 Thermoreversible gelators are particularly attractive for vaginal application, as the 
material may pass through an applicator before forming a viscous gel upon contact with the body which 
enhances retention of bioactives to prolong local effect or absorption 5 at a site where retention is often 
poor. 
The most widely studied polymer which exhibits thermoreversible gelation is poloxamer 407 (also called 
Pluronic F127). Poloxamer 407 is an ABA triblock copolymer with the structure poly(ethylene glycol)101  
block  poly(propylene glycol)65  block  poly(ethylene glycol)101.
6 Heating concentrated (> 15 % w/v) 
poloxamer 407 solutions results in a hierarchical process of desolvation of the poly(propylene glycol) 
block, which drives micellization and in turn the formation of a face-centred cubic mesophase gel.7 This 
property makes poloxamer 407 an attractive excipient for topical use, where the bodys heat may trigger 
gelation. 8 However, poloxamer 407 has several drawbacks including: a low Tgel of ca 25 °C and below,9 
rapid dissolution, and low mucoadhesion.6 Thus, there is a need for novel thermoreversible gelators with 
modulated properties.
Poly(N-isopropyl acrylamide)  block  poly(ethylene glycol)  block  poly(N-isopropyl acrylamide) 
(PNIPAM-PEG-PNIPAM) exhibits thermoreversible gelation in aqueous solution.10 PNIPAM exhibits a lower 
critical solution temperature (LCST), resulting in a coil-to-globule transition above a critical temperature, 
typically 32 °C.11 In the PNIPAM-PEG-PNIPAM copolymers, this transition leads to the formation of 
micelles, believed to have flower-like or fractal-like structures depending on molecular weight.12,13 At high 
concentrations (above ca 20 % w/v), PNIPAM-PEG-PNIPAM forms physical gels, hypothesized to be a 
result of physical entanglement of PNIPAM blocks,14 though this phenomenon has been studied in only a 
limited number of publications.  It has previously been demonstrated that 20 % (w/v) solutions of a 
PNIPAM (2.3 kDa)  PEG (4.6 kDa) - PNIPAM (2.3 kDa) copolymer undergo transition to a gel state when 
warmed above ca 26 °C.14 Teodorescu et al10 studied molecular weight effects on PNIPAM-PEG-PNIPAM 
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gelation at concentrations of 20 % (w/v) and below, varying PEG molecular weight between 1 and 6 kDa 
and PNIPAM between 5 and 30 kDa. It was found that only 4 and 6 KDa PEG with 20 or 30 kDa PNIPAM 
blocks resulted in gel formation, as determined by rheometry, with Tgels of 38-43 °C. De Graaf et al have 
demonstrated PNIPAM (16 kDa)  PEG (6 kDa)  PNIPAM (16 kDa) and PNIPAM (32 kDa)  PEG (6 kDa)  
PNIPAM (32 kDa) exhibited gelation temperatures of 35 and 33 °C in phosphate buffered saline, allowing 
them to form a gel when injected into mice.15 This gel released paclitaxel in a controlled fashion and did 
not cause acute systemic toxicity. PNIPAM-PEG-PNIPAM is a potential thermoreversible gelator for topical 
drug delivery. However, understanding of its behaviour in drug delivery is limited and there are no studies 
evaluating its performance for topical application. Additionally, the solubilisation of drugs in concentrated 
PNIPAM-PEG-PNIPAM is limited,15 and there are no studies of saturation solubilisation and release in 
these systems. Furthermore, a critical evaluation of this novel material against poloxamer 407 has not 
been conducted. In order for novel excipients to translate into biomedical applications, clear advantages 
of these materials over the current approaches must be demonstrated. While gels are a traditional dosage 
form for topical application, there is a drive a generate novel materials with added functionality,16 and 
translation must be considered whilst driving this innovation.
In this research we study thermoreversible gelation in PNIPAM-PEG-PNIPAM with a view to topical drug 
delivery. The effect of concentration on Tgel and gel strength is studied, along with a critical evaluation of 
rheological performance against poloxamer 407. The stability of these materials is also reported for the 
first time. The materials are then compared side-by-side for the preparation of vaginal formulations, as 
an exemplar mucosal route, revealing a fundamental understanding of the behaviour of hydrophilic and 
hydrophobic drugs in these thermoreversible gelators.
Experimental
Materials
N-isopropyl acrylamide (NIPAM) (97 %), copper (I) bromide (CuBr) (98 %), tetrahydrofuran (THF) (99 %) 
and triethylamine (99.5 %) were purchased from Sigma-Aldrich (U.K.). Tris[2-(dimethylamino)ethyl]amine 
(Me6TREN) (99 %) and 2-bromoisobutyryl bromide (BiBB) (97 %) were purchased from Alfa Aesar (U.K.). 
Isopropyl alcohol (99 %) and dichloromethane (99 were purchased from Fisher Scientific (U.K.). Bipyridine 
(99 %), dimethylaminopyridine (DMAP) (97 %) and PEG 10 kDa were purchased from Aldrich (U.K.). 
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Aluminium oxide, neutral, Brockmann I was purchased from Acros Organics (U.K.).  Dialysis tubing with a 
molecular weight cut off (MWCO) of 3500 Da was purchased from Medicell Membrane Ltd (U.K.) and 
soaked in deionised H2O before use. GPC EasiVial poly(methyl methacrylate) mixed standards and a 
poly(methyl methacrylate) single standard (72 kDa) were purchased from Agilent (U.K.). Deionised H2O 
was used in all experiments. All reagents were used as supplied, unless otherwise indicated.
Vaginal fluid simulant (VFS) was prepared by dissolution of NaCl (3.510 g, 0.060 mol), KOH (1.400 g, 0.025 
mol), Ca(OH)2 (0.222 g, 0.003 mol), bovine serum albumin (0.018 g), lactic acid (2.000 g, 0.022 mol), acetic 
acid (1.000 g, 0.011 mol), glycerol (0.160 g, 0.002 mol), urea (0.400 g, 0.007 mol) and glucose (5.000 g, 
0.028 mol) in 1 L of deionised water. The solution was then adjusted to pH 4 with 1 M hydrochloric acid. 
This formula follows that recommended by Owen and Katz.17
Porcine vaginal tissue was purchased from WetLab (U.K.) and supplied frozen. The porcine vaginal mucosa 
was removed by incision with a scalpel. Once the tissue was removed it was cut into 1 cm2 squares which 
were attached to the texture analyse probe using adhesive pads.
Synthesis of PEG macronitiator
A 10 kDa PEG macroinitiator was synthesised using reported methods.18 DMAP (1.17 g, 9.6 mmol) in 
anhydrous dichloromethane (8 mL) was mixed with triethylamine (0.89 mL, 6.4 mmol) and cooled to 0 °C. 
BiBB (1.97 mL, 16.0 mmol) in anhydrous dichloromethane (8 mL) was then added to the DMAP and 
triethylamine solution. A solution of PEG (10 kDa, 16.0 g, 1.6 mmol) in dichloromethane (160 mL) was 
subsequently added dropwise over 1 h. When the addition of PEG was complete, the reaction was allowed 
to rise to room temperature and the reaction allowed to proceed with stirring for 18 h. The solution was 
filtered, and approximately half of the solvent in the filtrate removed in vacuo. The PEG initiator was then 
precipitated in cold diethyl ether (480 mL) and filtered. The crude PEG macroinitiator in the retentate was 
then recrystalised from absolute ethanol (300 mL) overnight. The resulting solid was filtered and washed 
with cold diethyl ether and dried in vacuo (Yield = 86.5 %). 
Synthesis of PNIPAM98-PEG122-PNIPAM98 by atom-transfer radical polymerisation (ATRP)
NIPAM was polymerised from the PEG macroinitiator by ATRP following established procedures.12 Firstly, 
the CuBr catalyst (28.7 mg, 200 µmol) was sealed in a round bottom flask and degassed for 30 min by 
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nitrogen purging. Separately, the Me6TREN ligand (53.5 µL, 200 µmol), NIPAM monomer (2.0 g, 17.7 
mmol) and PEG 10 kDa macroinitiator (1.0 g, 100 µmol) were dissolved in deionised water (10 mL), within 
a sealed round bottomed flask. The solution was then degassed by nitrogen bubbling for 30 min. The 
solution containing ligand, initiator and monomer was then transferred to the flask containing the catalyst 
via a degassed syringe. The reaction was allowed to proceed with stirring at room temperature. Samples 
were taken at regular intervals using a degassed syringe and analysed using GPC to monitor the 
polymerisation. Once polymerisation ceased (24h), the reaction mixture was dried in vacuo and dissolved 
in THF (10 mL). This solution was passed through a short length of neutral aluminium oxide (Brockmann 
I) to remove the catalyst-ligand complex. The product was then dissolved in H2O (10 mL) and dialysed 
against water using cellulose membrane (MWCO ~ 3500 Da) for 48 h. The resulting solution was then 
freeze dried yielding a white solid, which was analysed using IR, NMR and GPC (Yield = 74. 3 %).
Characterisation of polymer structure and molecular weight
1H NMR was performed on an Oxford Instruments ECA600 600 MHz NMR spectrometer with Delta 4.3.6 
software. All samples were measured in CDCl3. All spectra were analysed using MNOVA by Mestrelab 
(Spain). IR spectroscopy was performed on a Perkin Elmer Fourier Transform Infra-red (FTIR) 
Spectrometer Frontier with a Perkin Elmer Universal ATR Sample Accessory. A wavelength range of 650-
4000 cm-1 was used with a resolution of 4 cm-1. The instrument was cleaned with isopropyl alcohol before 
and after use.
Molecular weights were determined using an Agilent 12600 Infinity II GPC equipped with a refractive index 
(RI) detector an a Varian PLGel 5 µm mixed D column which ran DMF with 0.1 % LiBr as an eluent, at a 
flow rate of 0.4 mL/min with the column and detector held at 30 °C. 
Rheological evaluation of polymer solutions
All samples for rheometry were prepared to the required concentration in deionised water or VFS and 
refrigerated overnight before measurements were taken. Rheology was performed on an AR 1500ex 
rheometer by TA instruments (U.S.A.) with a Julabo AWC100 cooling unit and a 40 mm plate geometry 
with a gap of 650 µm. Rheological measurements were taken in triplicate.
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Oscillatory stress sweeps were performed at 1 Hz between 1 and 1000 Pa at 37 °C. Frequency sweeps 
were measured at 37 °C between 0.1 and 10 Hz at a shear stress of 1 Pa.  Temperature ramps were 
performed at a frequency of 1 Hz and a shear stress of 1 Pa. The temperature was increased at a rate of 2 
°C per minute, from 15 to 50 °C. 
Reversibility of the phase transition was assessed by rheological measurement at 25 °C for 1 min, followed 
by 37 °C for 1 min, which was repeated once more. A 2 min equilibration period was included between 
temperature changes and the measurements were recorded at 1 Pa and 1 Hz.
To determine the gelation time, the temperature of the peltier plate was held at 25 °C for 1 min, then 
increased to 37 °C and held for a further 4 min. All measurements were made at a constant shear stress 
of 1 Pa and a frequency of 1 Hz.  The time taken for G to exceed G at 37 °C was taken as the gelation 
time. 
Dissolution of polymer gels in VFS
The thermoreversible gelator (20 % w/v poloxamer 407 or 50 % w/v PNIPAM98-PEG122-PNIPAM98)  
dissolution rate was identified using a Copley USP II dissolution apparatus held at 37 °C with 400 mL VFS 
using an immersion cell developed in house consisting of a plastic cylinder with a closed weighted base, 
where the cylinder had a depth of 8.5 mm and a surface area of 306 mm2. The immersion cell was weighed 
and 2 mL sample was placed within. The cell was then placed in an oven for 5 minutes at 37 °C prior to 
starting the experiment to induce gel formation. The immersion cell was then weighed and placed into 
the AVF. The paddle was set to 50 rpm and the weight of the immersion cell was measured every 5 minutes 
to identify how much gel remained, until all the gel was dissolved. The weight percent of remaining gel 
was by expressed relative to the starting mass.
Investigation of the Influence of temperature-responsive polymers on the solubility of progesterone and 
tenofovir disoproxil fumarate
The effect of polymer on drug solubility was investigated using polymer concentrations ranging from 0.005 
to 10 mg/mL at both 25 and 37 °C. Drug (ca 5 mg) was added to the polymer solutions (1 mL) which were 
then placed in a water bath at either 25 or 37 °C and were stirred for 24 h. If the polymer solution was 
clear after 24 h, more drug (ca 5 mg) was added and the vials were again left for 24 h under constant 
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stirring, this process was repeated until the solutions remained turbid for 24 h. The turbid solutions were 
then centrifuged, and the clear supernatant was then analysed by HPLC using a validated HPLC procedure 
(ESI). If a linear relationship between drug solubility and polymer concentration was observed, the critical 
micelle concentration (CMC) was calculated (equation S4, SI). The CMC was then used alongside 
experimental data to calculate the solubilising power of the polymer (Equation S5, SI). Following the 
calculation of the polymer solubilising power, the micelle/water partition coefficient was calculated 
(Equation S6, SI). Each polymer concentration was investigated in triplicate. The effect of progesterone 
saturation on micellisation was investigated at 10 mg/mL using dynamic light scattering on a Zetasizer 
Nano-NS (Malvern, U.K.). Undissolved progesterone was removed prior to analysis by passage through a 
0.4 S microfilter. 
The saturated solubility of progesterone and tenofovir disoproxil fumarate in water and the concentrated 
thermoreversible gelator solutions was then investigated. The thermoreversible gelators (20 % w/v 
poloxamer 407 or 50 % w/v PNIPAM98-PEG122-PNIPAM98) were prepared and stored in the fridge 
overnight. On the following day, 1 mL of thermoreversible gelator or water was transferred to a sample 
vial and progesterone or tenofovir disoproxil fumarate (ca 5 mg) added. The solutions were then stored 
in a water bath at either 25 or 37 °C with constant stirring. If after 24 h the solution was clear, more drug 
was added and again left for 24 h in the water bath with constant stirring. This process was repeated until 
the solution remained turbid for 24 h. Excess drug was then removed by centrifugation (10 min at 14500 
rpm) and the clear supernatant was analysed by HPLC. Each experiment was performed in triplicate.
Release of progesterone and tenofovir disoproxil fumarate from thermoreversible gelators
The release of progesterone and tenofovir disoproxil fumarate from the thermoreversible gelators (20 % 
w/v poloxamer 407 or 50 % w/v PNIPAM98-PEG122-PNIPAM98) was investigated using Franz diffusion cells 
equipped with a cellulose membrane (MWCO 3.5 kDa) at both 25 and 37 °C. The experiments used Franz 
cells with an average phosphate buffer saline (PBS) receiver fluid volume of 12.3 mL and an average bore 
area of 174 mm2. The release of 50 µg/mL progesterone or 200 µg/mL tenofovir disoproxil fumarate was 
investigated, where this concentration did not violate sink conditions. A 20 % w/v ethanol solution in PBS 
containing 50 µg/mL progesterone and a 200 µg/mL tenofovir disoproxil fumarate solution in PBS were 
used as controls. The Franz cells were then placed into a water bath for 30 min to allow the receiver fluid 
to reach the temperature of the surrounding water (25 or 37 °C). All Franz cells were dosed with 200 µL 
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of sample and the release of drug measured at regular intervals by sampling receiver fluid (500 or 200 µL 
for the progesterone and tenofovir disoproxil fumarate respectively). Receiver fluid was replaced with an 
equal volume of pre-warmed PBS. The samples were analysed by HPLC (method and calibration (Figure 
S1) in SI). The experiment was repeated 4 times.
Assessing the adhesion and mucoadhesion of thermoreversible gelators
The adhesion and mucoadhesion of the thermoreversible gelators (20 % w/v poloxamer 407 or 50 % w/v 
PNIPAM98-PEG122-PNIPAM98) was assessed using a TA.XT Plus Texture Analyser (Stable Micro Systems, UK) 
with a poly(propylene) probe with a surface area of 1.25 cm2. This probe was used to determine adhesion 
values, whereas mucoadhesion was evaluated using porcine vaginal mucosa tissue (WetLab, UK). The 
thermoreversible gelator was placed into a water bath at 25 °C, the probe was lowered until contact 
between the probe or vaginal mucosa tissue was made. The temperature of the water bath was then 
increased to 37 °C and held at this temperature for 2 min to ensure gel formation, and mimic in situ 
gelation. Once a gel had formed, the probe was withdrawn at a rate of 10.0 mms-1 until complete 
detachment was observed, as recommended in prior studies.19 The maximum force of detachment and 
the area under the force-displacement curve were determined using Texture Exponent 32 software 
(Stable Micro Systems, UK) and designated the force of adhesion and work of adhesion, respectively. 
All adhesion testing was performed 6 times. The mucoadhesion testing was performed using three 
different porcine vaginal tissues where three samples of vaginal tissue were taken from each vagina. Data 
was expressed as a mean of triplicate experiments (N=3), where N was the mean value of the three 
measurements taken from a single vagina. 
Stability of thermoreversible gelators 
The stability of thermoreversible gelators (20 % w/v poloxamer 407 or 50 % w/v PNIPAM98-PEG122-
PNIPAM98) was assessed over 12 weeks. The polymer solutions were prepared in HPLC vials sealed with 
parafilm and placed in the refrigerator (4°C) or in ovens set at 25 and 40 °C representing room 
temperature and accelerated storage conditions, respectively. At weekly intervals, the samples were 
lyophilised and the molecular weight determined by GPC, as described previously. Sufficient samples were 
prepared so that each weekly measurement was taken on a separate sample. The experiment was 
performed in triplicate.  
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Statistical analysis
All statistical analysis was conducted on Prism5 (GraphPad, USA). Data was analysed by one-way analysis 
of variance (ANOVA) with Tukey post-hoc analysis unless otherwise stated. Data presented as means ± 
standard deviation.
Results and discussion
PNIPAM98-PEG122-PNIPAM98 was synthesised in a two-step process by covalent attachment of an ATRP 
initiator to PEG122 using a simple SN2 reaction with DMAP-activated BiBB followed by ATRP polymerisation 
from the macroinitiator using a Cu(I)Br/ME6TREN catalyst/ligand complex (Figure 1 (i)).
12,18 GPC confirmed 
that the resultant copolymer had a monomodal molecular weight distribution with a polydispersity index 
of 1.88 (Figure 1 (iii)), in line with previous publications.12 The degree of polymerisation was calculated by 
1H NMR (Figure 1 (iv)), finding that the polymer had the structure PNIPAM98-PEG122-PNIPAM98. DOSY NMR 
(Figure S2, SI) unambiguously confirmed attachment of PNIPAM to PEG by demonstrating that the two 
blocks have the same diffusion coefficient. 
All blocks of PNIPAM98-PEG122-PNIPAM98 are water-soluble at room temperature, but the copolymer is 
expected to transition to an amphiphilic state when warmed due to the desolvation of PNIPAM. The 
comparator pharmaceutical excipient, poloxamer 407, is shown in figure 1 (ii). This ABA copolymer 
exhibits water solubility at temperatures below ca 20 °C but transitions to an amphiphilic state when 
warmed due to the desolvation of the central poly(propylene oxide) block. Desolvation of the central block 
leads to a hierarchical process of micelle formation (hydrodynamic radius ca. 10 nm) and subsequent 
packing into a face-centred cubic lattice to form a transparent gel mesophase.7,20 
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Figure 1. The synthetic route to PNIPAM98-PEG122-PNIPAM98 (i) and chemical structure of poloxamer 407 
(iii). PNIPAM98-PEG122-PNIPAM98 was characterised by GPC (ii) and 
1H NMR (iv).
The thermoresponsive gelation process exhibited by PNIPAM98-PEG122-PNIPAM98 was studied by 
rheometry with variation of polymer concentration between 20-50 % (w/v) (figure 2(i)). The copolymer 
exhibited dramatic increases in G and G above a critical temperature (Tthick), at ca 30-35 °C believed to 
be associated with the desolvation of PNIPAM.21 All rheograms exhibited a gelation temperature (Tgel) 
above ca 35 °C, at which point the absolute value of G surpassed that of G, indicative of a transition from 
a viscous fluid to an elastic gel state. These value of Tthick and Tgel are attractive for biomedical 
applications where the polymer solutions will have low viscosity at room temperatures, but thicken when 
warmed by the body. Poloxamer 407 exhibited a markedly different thermoresponsive gelation to 
PNIPAM98-PEG122-PNIPAM98. Low viscosity gels (G ca 100 Pa) were formed at 15 % (w/v), with Tgel at 45 
°C. Viscous gels (G ca 10kPa) were formed at 20 and 25 % (w/v) with Tgel < 25 °C. At 30 % (w/v) the 
materials were gels over the whole temperature range studied. 
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Figure 2. Temperature ramp rheograms of PNIPAM98-PEG122-PNIPAM98 (i) and poloxamer 407 (ii) with 
variation of concentration (% w/v) at a fixed shear stress (1 Pa) and frequency (1 Hz). G is presented as 
the dark colour, whilst the light colour corresponds to G. Data presented as mean ± standard deviation, 
n = 3.
Tgel, Tthick and the maximum absolute value of G reached (Gmax) were extracted from the rheograms 
shown in figure 2 and figure S3 (SI) and are presented in figure 3. PNIPAM98-PEG122-PNIPAM98 (Figure 3 (i)) 
exhibited a monotonic, near-linear, decrease in Tgel from 44 to 36 °C across the concentration range 
studied. A linear fit (R2 = 0.96) indicates that the rate of Tgel depression is -0.25 °C.g-1.dL, allowing tight 
control of Tgel over this range. Tthick decreased from 36 to 29 °C between 20 and 50 % (w/v) 
concentration, allowing thickening to occur upon warming by the body. An inverse proportionality 
between Tgel and concentration has previously been observed in PNIPAM- poly(N,N-
dimethylacrylamide)-PNIPAM solutions, and was attributed to the depressed LCST observed in PNIPAM 
solutions at high concentrations.22 Gmax increased with concentration from 1.5 kPa at 20 % (w/v) to a 
maximum of 12.7 kPa at 45 % (w/v). An increase in gel strength with concentration was also observed by 
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Kirkland et al22 when studying PNIPAM- poly(N,N-dimethylacrylamide)-PNIPAM. The authors rationalise 
this phenomenon using the theory of Semenov et al,23 that telechelic polymers with associating end-
groups form flower-like micelles bridged by polymer chains resulting in elasticity. Kirkland et al suggest 
that a greater number of polymer chains results in additional bridges formed between micellar domains, 
increasing viscosity.22 It is also conceivable that a greater number of micelles increases the degree of 
overlap between these aggregates, in a manner analogous to that observed in poloxamer 407.24 Values of 
Tgel for PNIPAM98-PEG122-PNIPAM98 were typically ca 5 °C greater than Tthick, whereas poloxamer 407 
gave a sharper transition at 20 and 25 % (w/v) with Tgel within 1 °C of Tthick. 
Poloxamer 407 exhibited a far greater dependence of Tgel on concentration than PNIPAM98-PEG122-
PNIPAM98 (Figure 3 (ii)), with Tgel decreasing from 45 to 21 °C as the concentration was increased from 
15 to 25 % (w/v). At 30 % (w/v) no Tgel was determined, with the rheograms exhibiting G>G at all 
temperatures. These findings are in line with established phase behaviour of pluronics.20 Of the 
concentrations studied, only 17.5 and 20 % (w/v) poloxamer 407 samples (Tgel of 30 and 5 °C, 
respectively)  exhibited Tthick/Tgel at a temperature suitable for in situ thickening upon contact with the 
body (i.e. 25°C < Tthick < 37 °C), albeit with a Tgel which may be reached at real room temperatures in 
warmer climates, e.g. WHO climatic zones III and IV (30 °C).25 The Tthick of 15 % poloxamer 407 was at 
body temperature (37 °C). Poloxamer 407s Gmax was proportional to concentration, and had a value of 
6.5 kPa at 17.5 % (w/v) poloxamer 407 and 12.7 kPa at 20 % (w/v). Due to the larger gel strength of the 
20 % (w/v) formulation and its prevalence in the literature,6 this concentration was selected for 
comparison with PNIPAM98-PEG122-PNIPAM98  in future experiment. It is known that poloxamer 407 forms 
a gel via the packing of micelles into a cubic structure and increasing concentration leads to an increased 
volume fraction of micelles, and thus a greater degree of overlap between the micelles.24 The increase in 
Gmax with concentration observed for the poloxamer samples is attributed to this greater degree of 
overlap and thus internal friction. The gels formed by 50 % (w/v) PNIPAM98-PEG122-PNIPAM98 were 
translucent, whilst the 20 % (w/v) poloxamer 407 gels were clear (figure 3 (iii)). This indicates that the 
poloxamer micelles are sufficiently small to avoid scattering of visible light, but that the PNIPAM98-PEG122-
PNIPAM98 aggregates are larger and the Tyndall effect is observed. 
Overall, the rheological behaviour of PNIPAM98-PEG122-PNIPAM98 and poloxamer 407 with temperature 
are distinct. Where 20-50 % (w/v) PNIPAM98-PEG122-PNIPAM98 solutions would increase in viscosity when 
warmed from room to body temperature, this was observed only in 17.5 and 20 % (w/v) poloxamer 407 
solutions. The lower concentration dependence of Tgel seen for PNIPAM98-PEG122-PNIPAM98 is attractive 
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determine the time required for the gel phase to form (figure 4 (i)). PNIPAM98-PEG122-PNIPAM98 (50 % 
(w/v)) was oscillated at 1 Pa shear stress and a frequency of 1 Hz while temperature was varied. The 
sample was set constant to room temperature (25 °C) for 60 s before holding at body temperature (37 °C) 
for 240 s. The transition from 25 to 37 °C lead to immediate thickening of the sample, which formed a gel 
after 87 ± 5 s and plateaued at a G of ca 700 Pa. This relatively long gelation time may have clinical 
implications, where a patient may be asked to remain still until gel formation has occurred. The same 
experimental procedure for poloxamer 407 (20 % (w/v) (Figure S4, SI) gave a time for gel of 27 ± 5 s, with 
a plateau at ca 5.5 kPa indicating a more rapid and rigid gel formation for this sample. The PNIPAM98-
PEG122-PNIPAM98 gel formed at 37 °C was subjected to an oscillatory stress sweep which demonstrated 
thinning above ca 200 Pa with a gel yield observed at 247 ± 72 Pa, which was not significantly different (p 
> 0.05 by T-test) than poloxamer 407 (20 % (w/v) which exhibited a yield at 256 ± 58 pa (Figure S5, SI). The 
yield strength is an indicator of the force required to make the sample undergo viscous flow, and may be 
taken as the point where G becomes lower than G during an oscillatory stress sweep in the gel phase.27  
An oscillatory frequency sweep of PNIPAM98-PEG122-PNIPAM98 (50 % (w/v)) at 37 °C confirms that the 
structure is a rheological gel, with G>G at all frequencies measured (figure 4 (iii)). Finally, the PNIPAM98-
PEG122-PNIPAM98 (50 % (w/v)) was cycled between 25 and 37 °C at 1 Pa and 1 Hz (figure 4 (iv)), which 
indicated that the thermoresponsive gelation process was reversible and repeatable.
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Figure 4. (i) Determination of gelation time for PNIPAM98-PEG122-PNIPAM98 (50 % (w/v)). (ii) Oscillatory 
stress sweep of PNIPAM98-PEG122-PNIPAM98 (50 % (w/v)), and (iii) oscillatory frequency sweep. (iv) thermal 
cycling of PNIPAM98-PEG122-PNIPAM98 (50 % (w/v)) to demonstrate reversibility of the gelation process. G 
and G are shown as dark and light blue markers, respectively. Data presented as mean ± standard 
deviation, n = 3.
The effect of physiological fluids on the phase transition of PNIPAM98-PEG122-PNIPAM98 and poloxamer 
407 was then evaluated by preparing polymer solutions in VFS (Figure 5).17 The rheological temperature 
ramp for PNIPAM98-PEG122-PNIPAM98 (50 % (w/v)) was altered considerably in VFS relative to deionised 
water. Tgel shifted to 32.9 ± 0.2 °C in VFS relative to 35.8 ± 0.2 °C in deionised water. This depression of 
Tgel was also seen in poloxamer 407 which formed a gel at 22.3 ± 0.4 °C in VFS compared to 24.7 ± 0.2 °C 
in deionised water. The depression of Tgel seen in PNIPAM98-PEG122-PNIPAM98 is attributed to salting-out 
of the PNIPAM block. Chaotropes have been shown to reduce LCSTs through an increased surface tension 
between PNIPAM hydrophobic domains (i.e. isopropyl groups and the carbon backbone) and their 
hydration layer.28 Tgel depression in poloxamer 407 is also attributed to salting-out, where salts are know 
to entropically promote the micellization process.29 VFS did not affect Gmax of PNIPAM98-PEG122-
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PNIPAM98 (50 % (w/v)), which was 11.7 ± 1.5 and 11.2 ± 1.8 kPa in VFS and deionised water, respectively 
(p < 0.05 by T-test). However, the depression in Tgel did result in a greater value of G at 37 °C for 
PNIPAM98-PEG122-PNIPAM98 (50 % (w/v)) in VFS compared in deionised water, giving values of 4.8 ± 2.8 
kPa and 1.1 ± 0.8 kPa, respectively. G of poloxamer 407 (20 % (w/v)) at 37 °C was unaffected by the 
presence of VFS, with both VFS and deionised water leading to values of G of ca 13 kPa at this 
temperature.
Figure 5. Temperature ramp rheograms of 50 % (w/v) PNIPAM98-PEG122-PNIPAM98 (i) and 20 % (w/v) 
poloxamer 407 (ii) in VFS at a fixed shear stress (1 Pa) and frequency (1 Hz). G and G are shown as dark 
and light markers, respectively. Data presented as mean ± standard deviation, n = 3.
A significant limitation of poloxamer 407 as a thermoresponsive gelator is its rapid dissolution in 
physiological fluids.6 20 % (w/v) solutions of poloxamer 407 dissolved in VFS within 60 min (figure 6). 
PNIPAM98-PEG122-PNIPAM98 (50 % (w/v)) had a significantly (p<0.05) greater resistance to dissolution, 
requiring 230 min for dissolution to occur. A control of 50 % (w/v) poloxamer 407 dissolved after 140 min, 
which indicated that this difference is not solely explained by concentration. It is hypothesised that where 
poloxamer 407 gels are composed of non-interacting polymeric micelles, the liberation of micelles into 
the dissolution medium occurs rapidly. PNIPAM98-PEG122-PNIPAM98 micelles are thought to be bridged by 
polymeric unimers which reduce the favourability of micelle liberation into the dissolution medium.14,23 
These experiments were conducted in a large excess of dissolution media, and the dissolution process in 
the real, smaller, volumes of physiological fluid present in vivo is likely to occur over a longer period of 
time.
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Figure 6. Dissolution of PNIPAM98-PEG122-PNIPAM98 50 % (w/v) (blue) and 20 (red), 30 (green) and 50 % 
(w/v) (black) poloxamer 407 in VFS. Data presented as mean ± standard deviation (n = 3).
The mucoadhesion of poloxamer 407 is weak,30 which limits its residence time on mucosal membranes. 
Mucoadhesion is mediated by several different factors, which are not mutually exclusive. Briefly, 
entanglements may occur between macromolecules in the dosage form and mucin glycoproteins coating 
the mucosa, which are supported by non-covalent interactions, enhancing adhesion.31 The viscosity of a 
gel will enhance retention, whilst the movement of moisture from the mucosa to the dosage form will 
either improve or decrease mucoadhesion depending on levels of hydration.32 Several other theories 
exist.33 The most common method to determine mucoadhesion is by measuring the force-displacement 
curve during removal of the dosage form from a membrane, where the peak force is termed the force of 
adhesion and the total area under the curve is the work of adhesion.34  These adhesion processes were 
studied for 50 % (w/v) solutions of PNIPAM98-PEG122-PNIPAM98 as well as 20, 30, and 50 % (w/v) poloxamer 
407. Only 20% (w/v) solutions of poloxamer 407 exhibit Tgel at a relevant temperature (25 °C), but 30 and 
50 % (w/v) solutions were explored to account for differences in concentration between the two 
thermoreversible gelators and understand whether adhesion processes are affected by chemical 
structure or concentration. Firstly, the adhesion of PNIPAM98-PEG122-PNIPAM98 and poloxamer 407 to a 
poly(propylene) probe was assessed (figure 7). In this control experiment, van der Waals forces are 
believed to be the major contributor to adhesion. The data demonstrates that the adhesion of poloxamer 
407 increases with concentration, and that 50 % (w/v) solutions of PNIPAM98-PEG122-PNIPAM98 and 
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poloxamer 407 had equivalent (p > 0.05) adhesion to the probe. The mucoadhesion of 20 % (w/v) 
poloxamer 407 and 50 % (w/v) PNIPAM98-PEG122-PNIPAM98 is shown in figure 7. PNIPAM98-PEG122-
PNIPAM98  (50 % (w/v)) had greater force and work of adhesion than 20 % (w/v) poloxamer 407 (p < 0.01) 
which is desirable for mucosal drug delivery. A control of 50 % (w/v) poloxamer 407 was equivalent to the 
PNIPAM98-PEG122-PNIPAM98  (50 % (w/v) which demonstrates that this enhanced adhesion is likely to be 
related to concentration, rather than enhanced specific intermolecular interactions between polymer and 
mucosa. However, concentrations of poloxamer 407 above 20 % (w/v) did not exhibit a Tgel in the range 
required and thus is not appropriate for in situ gelation with topical administration. Overall, PNIPAM98-
PEG122-PNIPAM98 allows the formation of in situ gelators (25 < Tgel < 37 °C) at 50 % (w/v), which imparts 
a greater level of mucoadhesion than seen for 20 % (w/v) poloxamer 407. 50 % (w/v) poloxamer 407 had 
equivalent mucoadhesion to 50 % (w/v) PNIPAM98-PEG122-PNIPAM98 but it is not a thermoreversible 
gelator, existing in a gel phase at all temperatures studied.
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Figure 7. Adhesion (i) and mucoadhesion (ii) of 50 % (w/v) PNIPAM98-PEG122-PNIPAM98  and poloxamer 407 
onto a poly(propylene) probe or porcine vaginal tissue, respectively. 
The thermoresponsive polymers were then evaluated for their ability to solubilise two drugs relevant to 
intravaginal drug delivery: progesterone and tenofovir disoproxil fumarate. Progesterone is administered 
intravaginally to treat low fertility, premenstrual syndrome, and puerperal depression, as well as support 
in vivo fertilisation and reduce the risk of pre-term delivery in pregnancy.3538 Intravaginal tenofovir 
disoproxil fumarate has been shown to reduce transmission of HIV in a macaque model.39 In addition to 
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their relevance to vaginal drug delivery, progesterone and tenofovir disoproxil fumarate were selected as 
they have large differences in their water solubilities. Progesterone was determined to have a water 
solubility of 9.8 ± 0.1 µg/mL at 25 °C, whilst tenofovir disoproxil fumarates solubility was approximately 
1000-fold greater at 9.5 ± 1.0 mg/mL. The solubility of the two drugs in the presence of the polymers at a 
range of concentrations between 5 µg/mL and 10 mg/mL was determined at 25 and 37 °C (figure 8). It 
was found that for both polymers the solubility of progesterone (figure 8 (i)) was greatly increased above 
a critical concentration, believed to be the critical micelle concentration (CMC). The CMC could then be 
extracted from the data, giving values of 0.26 and 1.88 mg/mL at 25 °C for PNIPAM98-PEG122-PNIPAM98  
and poloxamer 407 respectively, which rose to 0.68 and 1.95 mg/mL at 37 °C. The CMC of poloxamer 407 
is on the same order of magnitude as that reported previously (ca 3 mg/mL) for the pure polymer,40 and 
the deviation is attributed to the presence of progesterone, as reported for other drugs.41 Tenofovir 
disoproxil fumarate (figure 8 (ii)) solubility was not enhanced by increasing concentration of either 
polymer, even above the CMCs. The data indicates that the formation of micelles occurs for both polymers 
above a CMC at 25 and 37 °C, at which point the micelles provide a locus for solubilisation for the relatively 
hydrophobic progesterone, but tenofovir disoproxil fumarate is excluded from the micelle. The solubilities 
of both drugs are increased at 37 °C, above and below the critical micelle concentration, with a more 
pronounced effect seen in tenofovir disoproxil fumarate which is attributed to its enhanced water 
solubility at this temperature.
Dynamic light scattering revealed a pronounced influence of progesterone on the micellization of 
PNIPAM98-PEG122-PNIPAM98. 10 mg/mL solutions of PNIPAM98-PEG122-PNIPAM98 exhibited no detectable 
particulates at 25 °C but when warmed to 37 °C transitioned to a 138 nm nanoparticle, which shrunk and 
remained at a constant hydrodynamic diameter of ca 90 nm at temperatures at 40 °C and above (Figure 
S6, SI). In the presence of progesterone, nanoparticle aggregates were detected at 25 °C. Furthermore, at 
38 °C and above, a pronounced transition was observed (Figure 8 (iii)). The hydrodynamic diameter of the 
nanoparticles in the presence of progesterone at 25, 37, and 40 °C were 15 ± 1, 15 ± 1, and 73 ± 0 nm, 
respectively (Figure 8 (iv)), demonstrating the change in nanostructure associated with the transition at 
38 °C. It is hypothesised that the presence of progesterone drives the formation of micellar nanoparticles 
below the LCST-type transition of PNIPAM, which, when triggered by a rise in temperature, leads to the 
aggregation or rearrangement of these micelles. The size of these particles is close to those found without 
progesterone at 40 °C (88 ± 1 nm) (Figure 8 (iv)). Prior study of PNIPAM-PEG-PNIPAM reports PNIPAM (16 
kDa)  PEG (6 kDa)  PNIPAM (16 kDa) formed flower-like micelles with a hydrodynamic diameter of 62 
nm,13 whereas lower molecular weight PNIPAM (4 kDa)  PEG (6 kDa)  PNIPAM (4 kDa) formed fractal-
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like structures with hydrodynamic diameters of up to 400 nm.12 Due to the closer molecular weight of the 
constituent unimers, and similar hydrodynamic diameters, it is believed that PNIPAM98-PEG122-PNIPAM98 
forms flower-like micelles in a similar manner to PNIPAM (16 kDa)  PEG (6 kDa)  PNIPAM (16 kDa).
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Figure 8. Solubilisation of progesterone (i) and tenofovir disoproxil fumarate (ii) by PNIPAM98-PEG122-
PNIPAM98 (blue) and poloxamer 407 (red) at 25 and 37 °C (light and dark colours, respectively). Inset: 
schematic representation of the micellization process. iii) the scattering counts of a 10 mg/mL PNIPAM98-
PEG122-PNIPAM98 solution saturated with progesterone as a function of temperature. iv) hydrodynamic 
diameter of PNIPAM98-PEG122-PNIPAM98 nanoparticles saturated with progesterone at 25 (light blue), 37 
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(dark blue), and 40 (black) °C, and PNIPAM98-PEG122-PNIPAM98 without progesterone at 40 °C (black 
dashed).
The solubilising power and micelle:water partition coefficients of the polymer/drug mixtures were 
calculated from the progesterone solubilisation data in figure 8 (i) and are included in table 1.42 Briefly, 
the solubilising power reflects the unit mass increase in progesterone solubilised per unit mass of polymer, 
whereas the micelle:water partition coefficient reflects the concentration of drug within the micelle 
relative to that free in solution. PNIPAM98-PEG122-PNIPAM98 had a solubilising power approximately 1.5-
fold greater than poloxamer 407 at both temperatures, and a micelle:water partition coefficient around 
twice as large. These differences were demonstrated to be statistically significant by two-way ANOVA with 
Bonferroni post-hoc testing (p < 0.0001).  It is known that the greater the molecular weight of the relatively 
hydrophobic poly(propylene oxide) domains, the greater the solubilising power of poloxamers.43 The 
microphase separated NIPAM domains (DP:196) in PNIPAM98-PEG122-PNIPAM98 have a greater degree of 
polymerisation (and molecular weight) than the poly(propylene oxide) in poloxamer 407 (DP: 65) which 
may lead to a greater solubilising power. These considerations are balanced against the free energy of the 
solubilisation process, which will differ between the two polymers.43
Temperature increased the mean value of solubilising power for both polymers, however this increase 
was only statistically significant (p<0.05) for PNIPAM98-PEG122-PNIPAM98. As no structural transition was 
observed between 25 and 37 °C by dynamic light scattering, it is hypothesised that this small increase is 
the result of entropic effects favouring polymer-progesterone interactions at the elevated temperature. 
Poloxamer exhibited a structural transition at 26 °C (Figure S7, SI), increasing in hydrodynamic diameter 
from ca 9 to 22 nm, however this did not affect the solubilisation of progesterone.
Table 1. Solubilising power and micelle:water partition coefficients calculated from data presented in 
figure 8.
Solubilising power (x 10-3) Micelle:water Partition Coefficient
Polymer
25 °C 37 °C 25 °C 37 °C
poloxamer 
407
1.53 ± 0.07 1.65 ± 0.22 1.30 ± 0.06 1.21 ± 0.16
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PNIPAM98-
PEG122-
PNIPAM98
2.45± 0.22 2.86 ± 0.09 2.37 ± 0.08 2.54 ± 0.08
The saturation solubilities of progesterone and tenofovir disoproxil fumarate were then evaluated in the 
thermoreversible gels at high concentrations (figure 9). Strikingly, progesterone solubility is dramatically 
enhanced at 37 °C, relative to 25 °C, in the polymer solutions where the effect is small in water alone. This 
has important implications for drug delivery across a membrane, where liberation of drug from a dosage 
form is dictated by its thermodynamic activity within that base.44 The greater the degree of saturation, 
the greater the driving force for liberation. If progesterone is loaded into the solutions at room 
temperature then applied to the body and warmed then the thermodynamic activity is expected to 
decrease, thus liberation from the dosage form is expected to be slowed at this higher temperature. 
Despite the differences in solubilising power and concentration of the two polymers, progesterone 
saturation solubility in both polymer mixtures at 37 °C was equivalent, at 505.0 ± 7.8 and 504.8 ± 30.2 
SE for poloxamer 407 and PNIPAM98-PEG122-PNIPAM98, respectively, equivalent to a ca 45-fold 
increase relative to the saturation solubility in water (11.3 µg/mL). The molarities of the two solutions are 
approximately 16.5 and 18.2 mM for poloxamer 407 and PNIPAM98-PEG122-PNIPAM98 respectively, and 
the greater solubilising power of PNIPAM98-PEG122-PNIPAM98 is expected to lead to a much larger increase 
in progesterone solubility in this material. However, nanostructures present at the low concentrations 
studied for solubilising power calculations (< 10 mg/mL) may not be equivalent to those found at 50 % 
(w/v) in the PNIPAM98-PEG122-PNIPAM98. It is known that poloxamer exists as spherical micelles of 
approximately 10 nm diameter across a wide range of concentrations, however the nanostructure of the 
PNIPAM98-PEG122-PNIPAM98 materials at 50 % (w/v) has never been studied and block copolymers may 
exist in different phases dependent on concentration.24 It is further suggested that the high concentration 
of the PNIPAM98-PEG122-PNIPAM98 has driven the micellar transition observed in figure 8 (iii) at 38 °C to a 
temperature lower than 37 °C, in line with the depression in Tgel seen at high concentrations by 
rheometry. The solubilising power of poloxamer 407 (table 1) would suggest that progesterone solubility 
would be unaffected by temperature, however behaviour at this high concentration (20 % w/v) may differ 
from that in dilute solution, as has been reported for micelle:water partition coefficients.45 
Tenofovir disoproxil fumarate is excluded from the micelles formed by either polymer, and as such the 
increase in solubility observed in these polymers at elevated temperatures is attributed solely to the 
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improvement in solubility caused by heat alone (Figure 9 (ii)). The reduction in solubility seen in the 
polymer samples is attributed to the decreased volume fraction of water in these mixtures. Adjusting for 
the phase volume of water accounts for this depression.   
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Figure 9. Saturation solubility of progesterone (i) and tenofovir disoproxil  fumarate (ii) in 20 % (w/v) 
poloxamer 407 (red) and 50 % (w/v) PNIPAM98-PEG122-PNIPAM98 (blue) at 25 and 37 °C (light and dark 
colours, respectively).
The liberation of drugs from the thermoreversible gelators across cellulose membrane was then explored 
at loading concentrations below the saturation limit (Figure 10), maintaining sink conditions throughout 
the experiments. Control solutions of each drug were included to ensure that permeation across cellulose 
membrane was not rate-limiting, and each of these experiments give a characteristic curve associated 
with donor depletion in finite dosing experiments.46 Tenofovir disoproxil fumarate release from the two 
polymer solutions was equivalent at 25 °C. However, drug release was significantly (p < 0.05) enhanced at 
37 °C for poloxamer 407 but remained constant in the case of PNIPAM98-PEG122-PNIPAM98. For example, 
at 8 h the cumulative release at 25 °C was 58.3 ± 1.5 % and 61.0 ± 3.8 % for PNIPAM98-PEG122-PNIPAM98 
and poloxamer 407, respectively, but 53.8 ± 4.3 % and 86.6 ± 5.3 % for the same samples at 37 °C. As drug 
release is occurring from a planar dosage form, the Higuchi model was applied to the data. This simple 
model is based on a linear fit to the fractional drug release with the square-root of time.47 The model gave 
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R2 > 0.98 in all cases, supporting the principle that the gels act as a matrix controlled release system from 
which Fickian diffusion occurs (Figure S8, SI).47 Heat will enhance diffusion out of the matrix when release 
is purely diffusion controlled as the Stokes-Einstein equation predicts that the diffusion coefficient of a 
molecule scales linearly with temperature, when viscosity is constant.48 The control, a solution of tenofovir 
disoproxil fumarate exhibits this phenomenon. In the poloxamer 407 samples, which are a gel at both 
temperatures tested, an enhanced release from the gels is attributed to the increased diffusion 
coefficient, despite the increased viscosity of the system. For PNIPAM98-PEG122-PNIPAM98,  a phase 
transition occurs between the two temperatures tested. The identical release rate at 37 °C relative to 25 
°C is attributed to the formation of this gel phase, which provides a more tortuous path for liberation to 
occur where tenofovir is known to be excluded from the micelles, counteracting the increased diffusion 
coefficient.47
Progesterone release from PNIPAM98-PEG122-PNIPAM98 and poloxamer 407 samples was dramatically 
different than that exhibited by tenofovir disoproxil fumarate. Progesterone release from PNIPAM98-
PEG122-PNIPAM98 at 25 °C followed Higuchi kinetics (Figure S8, SI), and 100 % of the drug was released 
after 32 h. Increasing the temperature to 37 °C retarded the release of progesterone significantly, with 
100 % drug liberated only after 144 h. This release profile did not fit the Higuchi model, but exhibited a 
good fit (R2: 0.98) to the Korsmeyer-Peppas power law, albeit with an extreme exponent (n = 2.42) 
designating non-Fickian super case II transport kinetics.49 This retardation of release from PNIPAM98-
PEG122-PNIPAM98 at 37 °C is attributed to the formation of the gel phase, which provides microphase 
separated domains in which drug solubilisation may occur, and from which liberation becomes 
disfavoured, prolonging the release until 144 h. Additionally, polymer entanglements and an increased 
tortuosity within the samples may contribute to this effect. Progesterone release from poloxamer 407 
was equivalent at 25 and 37 °C, where the material is in the gel phase at both temperatures. Both cases 
gave Higuchi diffusion-controlled release in the first 60 % of the profile (R2 > 0.98), which is consistent 
with prior studied of drug delivery across a membrane from poloxamer gels.8 This behaviour is 
substantially different than the PNIPAM98-PEG122-PNIPAM98 system which exhibited clear temperature-
dependence on drug release, and a switch from Higuchi kinetics to a non-Fickian release mechanisms. 
Higuchi kinetics following Fickian diffusion may be rationalised below the Tgel where release of drug is 
controlled by factors such as partitioning and the viscosity of the medium. Super case II kinetics have been 
reported for chemically cross-linked PNIPAM hydrogels,50 where Fickian diffusion is believed to be 
combined with polymer relaxation and possible swelling effects. This swelling/relaxation behaviour may 
combine with nanostructural rearrangement to give rise to the lengthy lag exhibited in the progesterone 
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release studies from PNIPAM98-PEG122-PNIPAM98  at 37 °C, though this was not explicitly studied. It has 
been demonstrated by DLS that progesterone drives the formation of aggregates even at low 
temperatures, and the slow depletion of progesterone from the gel may also lead to structural 
rearrangement. Pure PNIPAM hydrogels also exhibit the long lag time seen for PNIPAM98-PEG122-PNIPAM98 
at 37 °C.50 The release of progesterone from PNIPAM98-PEG122-PNIPAM98 was significantly slower than 
poloxamer 407 at 37 °C. For example, at 72 h,  75.5 ± 1.6 % of the entrapped progesterone was delivered 
from the 20 % (w/v) poloxamer 407 sample, where only 25.3 ± 6.7 % of the drug had been liberated from 
PNIPAM98-PEG122-PNIPAM98 (p<0.0001 by T-test). This gives the PNIPAM98-PEG122-PNIPAM98 an advantage 
over poloxamer 407 when the sustained release of hydrophobic drugs is required. The total 10 µg 
progesterone dose was delivered from the 200 µL PNIPAM98-PEG122-PNIPAM98 formulation over 6 days, 
requiring a 5 mL dose to achieve the approximately 250  µg delivered from the standard Crinone gel over 
the same period.51 
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Figure 10: Release of 50 µg/mL progesterone and 200 µg/mL tenofovir disoproxil fumarate from 50 % 
(w/v) PNIPAM98-PEG122-PNIPAM98 (blue) and 20 % (w/v) poloxamer 407 (red). A control formulation of the 
drugs dissolved in a 1:1 water:ethanol mixture (open circles) demonstrates that liberation from the 
polymer gel is rate-limiting. Please note that for the tenofovir release experiments, the next time point 
determined for the gels (24 h) contained 100 % drug liberation. 
The impact of progesterone and tenofovir disoproxil fumarate (50 µg/mL) on the rheology of the 
thermoreversible gelators was assessed by temperature ramp (figure S9). In the presence of 
progesterone, the gelation temperature of poloxamer 407 (20 %) remained at 25 °C. Whereas the gelation 
temperature of PNIPAM98-PEG122-PNIPAM98 (50 %) was slightly reduced from 35.8 ± 0.4 to 34.2 °C. It is 
known drug-polymer interactions may decrease the LCST of PNIPAM, which may explain this slight 
reduction in Tgel.52 The inclusion of progesterone resulted in a decrease in gel strength for poloxamer 407 
(20 %) from 12.7 ± 0.5 to 10.2 kPa while G Max of PNIPAM98-PEG122-PNIPAM98 did not vary, having values 
of 11.2 ± 1.8 and 10.7 kPa in undoped and progesterone-doped solutions, respectively.  Tenofovir 
disoproxil fumarate did not alter the gelation temperatures of poloxamer 407 (20 %) and PNIPAM98-
PEG122-PNIPAM98 (50 %), having values of 24 and 35.4 °C, respectively. Tenofovir disoproxil fumarate 
reduced G Max to 9.7 kPa in the poloxamer 407 samples, but the value measured for PNIPAM98-PEG122-
PNIPAM98 (10.2 kPa) was within the error of the undoped samples. Overall, the PNIPAM98-PEG122-
PNIPAM98 samples retained their ability to act as thermoreversible gelators after the addition of both 
model drugs.
The stability of P407 and PNIPAM98-PEG122-PNIPAM98 was assessed in aqueous solution at 4, 25, or 40 °C, 
reflecting refrigerated storage, storage at room temperature, and an accelerated storage condition, 
respectively (Figure 11). Accelerated storage at 40 °C aimed to predict longer-term storage at room 
temperature. GPC analysis demonstrated that both polymers exhibit small reductions in molecular weight 
over 12 weeks, with losses accelerated in the PNIPAM98-PEG122-PNIPAM98 sample at elevated 
temperatures. However, at 4 and 25 °C the reduction in number-average molecular weight of PNIPAM98-
PEG122-PNIPAM98 was not statistically significant (p<0.05). GPC traces (Figure 11 (i)) of poloxamer at weeks 
0 and 12 are near-identical, with the accelerated storage condition (red) exhibiting a small increase in a 
shoulder at low molecular weight. PNIPAM98-PEG122-PNIPAM98 traces exhibit a clear shift to a lower 
molecular weight under accelerated storage conditions (Figure 11 (ii)). Under all conditions the trace for 
PNIPAM98-PEG122-PNIPAM98 traces remained monomodal with no shoulder. Thus, hydrolysis was not 
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observed at the ester linkages present between individual polymer blocks, but amide hydrolysis is 
possible. Poloxamer 407 does not possess hydrolytically unstable ester or amide linkages, and its 
molecular weight remained constant throughout the study. This is the first report on the long-term 
stability of a PNIPAM copolymer in water. Future studies on the stability of the materials should expand 
this experiment in-line with ICH standards.53 Additionally, it is not known whether the degradation 
exhibited in the accelerated storage condition will be seen at 25 °C where typically only small 
extrapolations are made from this data when the degradation routes have been established.53
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Figure 11. Stability of poloxamer 407 (i) and PNIPAM98-PEG122-PNIPAM98 (ii) at 4, 25 and 40 °C. Variation 
in the number-average molecular weight is shown on the left. GPC traces are shown on the right, with 
week 0 shown in black, and week 12 at 4, 25 and 40 °C shown in green, blue and red, respectively.  
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Conclusions
This study investigates the use of thermoreversible PNIPAM98-PEG122-PNIPAM98  gelators as smart 
materials for topical administration for the first time, with a critical comparison to poloxamer 407.  The 
low dependence of Tgel on concentration allows PNIPAM98-PEG122-PNIPAM98 to exhibit in situ gelation at 
concentrations up to 50 % (w/v), where Tgel may be finely tuned to temperatures just below 37 °C. 
Thickening occurred only at temperatures above 28 °C, ensuring that increases in viscosity do not occur 
at room temperature. This gives the system advantages over poloxamer 407 where values of Tgel are 
highly concentration dependant. Additionally, of the poloxamer 407 concentrations examined, Tgel 
typically occurred near or below room temperature (25 °C), making the materials unattractive in warmer 
climates (e.g. WHO climatic zones II (25 °C), III (30 °C) and IV (30 °C)).25 PNIPAM98-PEG122-PNIPAM98 gels 
exhibit enhanced mucoadhesion and reduced dissolution compared to poloxamer 407, giving PNIPAM98-
PEG122-PNIPAM98 significant advantages for mucosal drug delivery, where these two attributes are linked 
to retention at the site of administration. PNIPAM98-PEG122-PNIPAM98 was also found to be stable in 
solution at room temperature over 12 weeks. 
The solubilisation and release of two drugs relevant to vaginal drug delivery was investigated. 
Progesterone was selected as a hydrophobic drug, and tenofovir disoproxil fumarate was used as a 
relatively hydrophilic species. PNIPAM98-PEG122-PNIPAM98 was able to greatly enhance the solubility of 
progesterone due to inclusion of the drug into polymer micelles, with a greater solubilising power than 
poloxamer 407, whereas tenofovir disoproxil fumarate was excluded from the micelles in both cases. The 
release of these two drugs was then evaluated using a Franz diffusion cell system at 25 and 37 °C. Release 
of progesterone from the poloxamer gels was identical at both temperatures, whereas tenofovir 
disoproxil was liberated more rapidly at the elevated temperature. PNIPAM98-PEG122-PNIPAM98, however, 
gave an unusual temperature-responsive retardation of release of both drugs at elevated temperatures, 
controlling progesterone release over 6 days. This effect may be a means of controlling delivery of other 
xenobiotics or retaining drug on body surfaces for local effect. Overall, PNIPAM98-PEG122-PNIPAM98 
exhibits unique properties as a thermoreversible gelator for drug delivery with advantages over 
poloxamer 407 and could act as an advanced material for future topical therapies.
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Supporting information: Methods: HPLC methods and validation; calculation of critical micelle 
concentrations, solubilising powers, and micelle:water partition coefficients. Results: calibration curves, 
DOSY NMR, additional rheograms, DLS data for poloxamer 407, and mathematical fits to drug release 
profiles.
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PNIPAM98-PEG122-PNIPAM98 is explored as a thermoreversible gelator for topical administration, giving 
temperature-dependent release of progesterone over up to 6 days.
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